ADC Therapeutics (ADC Therapeutics) Price-to-Tangible-Book : (As of Apr. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Price-to-Tangible-Book?

As of today (2024-04-26), ADC Therapeutics's share price is $4.34. ADC Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-1.80. Hence, ADC Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for ADC Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 8 years, ADC Therapeutics's highest Price to Tangible Book Ratio was 10.18. The lowest was 4.76. And the median was 7.55.

ADCT's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.68
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, ADC Therapeutics's share price is $4.34. ADC Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $-1.80. Hence, ADC Therapeutics's P/B Ratio of today is .

ADC Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for ADC Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Price-to-Tangible-Book Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

7.55

10.18

4.76

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															4.76	6.52	-	-	-

Competitive Comparison of ADC Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, ADC Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADC Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's Price-to-Tangible-Book falls into.

ADC Therapeutics Price-to-Tangible-Book Calculation

ADC Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	4.34	/	-1.801
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

ADC Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.